We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
Read MoreHide Full Article
Key Takeaways
NeuroPace's IGE filing was not approvable in its current form, with the FDA seeking more clinical data.
NPCE plans added analyses and evidence, while management says the regulatory process remains open.
NeuroPace's Q2 RNS System revenues rose 21.3% to $22.5 million as IGE timing became less certain.
NeuroPace, Inc. (NPCE - Free Report) has hit a regulatory delay in its bid to expand the RNS System into idiopathic generalized epilepsy, or IGE. The FDA’s July 2026 response pushes out a potential growth catalyst beyond the company’s established focal epilepsy market.
The setback does not end the IGE opportunity, but it makes timing less predictable. Until the review advances, execution in the existing RNS franchise carries more weight for NeuroPace’s growth outlook.
NeuroPace’s FDA Setback Delays the IGE Opportunity
The FDA informed NeuroPace that its IGE premarket approval supplement was not approvable in its current form. The agency requested more information on the clinical benefit observed across patient subgroups, including by baseline generalized tonic-clonic, or GTC, seizure frequency, and on the clinical meaningfulness of reducing GTC seizures.
Management said the agency’s response was not a disapproval and that discussions remained interactive. The questions were not related to safety, leaving NeuroPace with a regulatory process that is delayed rather than closed.
NeuroPace is pursuing the FDA’s Submission Issue Request process before amending the filing. Management expects that meeting to help align the company and agency on the content of the amendment before submission.
The planned response may include additional subgroup analyses, patient- and physician-reported outcomes, relevant published and real-world evidence, and longer-term NAUTILUS data. At 24 months, evaluable patients showed a 100% median reduction in GTC seizures. Management believes the amendment may be reviewed without resetting the full 180-day clock, although the FDA retains discretion.
NeuroPace’s Focal Epilepsy Business Carries More Weight
Second-quarter RNS System revenues rose 21.3% year over year to $22.5 million. Active prescribers, active accounts and the patient pipeline reached record levels, while the company continued expanding relationships with community neurologists and Level 3 epilepsy programs to build referral pathways into implanting centers.
That execution matters more while IGE timing is uncertain. The broader neuromodulation market also includes Medtronic plc (MDT - Free Report) , whose deep brain stimulation system is indicated for certain adults with refractory partial-onset epilepsy, and LivaNova PLC (LIVN - Free Report) , whose VNS Therapy is indicated in the United States for patients age four and older with refractory partial-onset seizures. NeuroPace therefore needs continued adoption within its differentiated RNS platform while its indication-expansion process remains unresolved.
Image Source: Zacks Investment Research
NPCE’s IGE Delay Also Pushes Back Commercial Upside
A favorable FDA decision would expand NeuroPace’s addressable population, but approval alone would not immediately make IGE a material revenue contributor. Broader payer coverage, clinician training and commercial preparation would still be required after authorization.
Further regulatory delays could therefore shift more than the approval date. They could also postpone market expansion and the operating leverage investors may expect as NeuroPace spreads commercial and development spending across a larger revenue base. The company’s 2026 revenue guidance excludes any IGE contribution.
Image Source: Zacks Investment Research
NeuroPace’s Signals Keep the Risk-Reward Balanced
The IGE setback leaves NeuroPace with a credible path forward, but less visibility into when that opportunity can begin contributing to growth. In the meantime, the core focal epilepsy franchise, community referral expansion and continued RNS adoption remain the clearest operating measures to watch.
NPCE currently carries a Zacks Rank #3 (Hold) and a VGM Score of C. Its Growth Score of B and Momentum Score of B point to relatively favorable growth and momentum characteristics, while the Value Score of D is less supportive. Taken together with the unresolved IGE timeline, those signals favor a balanced view rather than an aggressive stance. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
View the Zacks #1 Rank List
Image: Shutterstock
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
Key Takeaways
NeuroPace, Inc. (NPCE - Free Report) has hit a regulatory delay in its bid to expand the RNS System into idiopathic generalized epilepsy, or IGE. The FDA’s July 2026 response pushes out a potential growth catalyst beyond the company’s established focal epilepsy market.
The setback does not end the IGE opportunity, but it makes timing less predictable. Until the review advances, execution in the existing RNS franchise carries more weight for NeuroPace’s growth outlook.
NeuroPace’s FDA Setback Delays the IGE Opportunity
The FDA informed NeuroPace that its IGE premarket approval supplement was not approvable in its current form. The agency requested more information on the clinical benefit observed across patient subgroups, including by baseline generalized tonic-clonic, or GTC, seizure frequency, and on the clinical meaningfulness of reducing GTC seizures.
Management said the agency’s response was not a disapproval and that discussions remained interactive. The questions were not related to safety, leaving NeuroPace with a regulatory process that is delayed rather than closed.
NeuroPace, Inc. Price and Consensus
NeuroPace, Inc. price-consensus-chart | NeuroPace, Inc. Quote
NPCE Still Has a Regulatory Path Forward
NeuroPace is pursuing the FDA’s Submission Issue Request process before amending the filing. Management expects that meeting to help align the company and agency on the content of the amendment before submission.
The planned response may include additional subgroup analyses, patient- and physician-reported outcomes, relevant published and real-world evidence, and longer-term NAUTILUS data. At 24 months, evaluable patients showed a 100% median reduction in GTC seizures. Management believes the amendment may be reviewed without resetting the full 180-day clock, although the FDA retains discretion.
NeuroPace’s Focal Epilepsy Business Carries More Weight
Second-quarter RNS System revenues rose 21.3% year over year to $22.5 million. Active prescribers, active accounts and the patient pipeline reached record levels, while the company continued expanding relationships with community neurologists and Level 3 epilepsy programs to build referral pathways into implanting centers.
That execution matters more while IGE timing is uncertain. The broader neuromodulation market also includes Medtronic plc (MDT - Free Report) , whose deep brain stimulation system is indicated for certain adults with refractory partial-onset epilepsy, and LivaNova PLC (LIVN - Free Report) , whose VNS Therapy is indicated in the United States for patients age four and older with refractory partial-onset seizures. NeuroPace therefore needs continued adoption within its differentiated RNS platform while its indication-expansion process remains unresolved.
Image Source: Zacks Investment Research
NPCE’s IGE Delay Also Pushes Back Commercial Upside
A favorable FDA decision would expand NeuroPace’s addressable population, but approval alone would not immediately make IGE a material revenue contributor. Broader payer coverage, clinician training and commercial preparation would still be required after authorization.
Further regulatory delays could therefore shift more than the approval date. They could also postpone market expansion and the operating leverage investors may expect as NeuroPace spreads commercial and development spending across a larger revenue base. The company’s 2026 revenue guidance excludes any IGE contribution.
Image Source: Zacks Investment Research
NeuroPace’s Signals Keep the Risk-Reward Balanced
The IGE setback leaves NeuroPace with a credible path forward, but less visibility into when that opportunity can begin contributing to growth. In the meantime, the core focal epilepsy franchise, community referral expansion and continued RNS adoption remain the clearest operating measures to watch.
NPCE currently carries a Zacks Rank #3 (Hold) and a VGM Score of C. Its Growth Score of B and Momentum Score of B point to relatively favorable growth and momentum characteristics, while the Value Score of D is less supportive. Taken together with the unresolved IGE timeline, those signals favor a balanced view rather than an aggressive stance. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.